Evidence map›Paper›PMID 30277016›Full record

SynthesisThoracic cancer2018

Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis.

Jun Wang, Jianjun Qin, Shaowu Jing, Qing Liu, Yunjie Cheng, Yi Wang, Feng Cao

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jun WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.ORCID 0000-0002-9733-1433
Jianjun QinDepartment of Thoracic Surgery, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China.
Shaowu JingDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qing LiuDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yunjie ChengDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yi WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Feng CaoDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough a clinical complete response (cCR) after chemoradiotherapy (CRT) could lead to a better prognosis, the choice of a following strategy, such as surgical or non-surgical approach, remains controversial.

methodsAll articles relevant to a comparison of surgical and non-surgical treatment (including further definitive chemoradiotherapy or active surveillance) for esophageal carcinoma patients with a cCR after CRT were retrieved for meta-analysis. The final date for data retrieval was 30 June 2018.

resultsFour retrospective studies including 648 patients met the inclusion criteria: 620 with squamous cell carcinoma and 28 with adenocarcinoma. The CRT + surgery group had an advantage over the non-surgery group in regard to two-year disease-free survival (DFS); however, the two groups showed similar results in five-year DFS. The CRT + surgery group had an advantage over the non-surgery group in two-year overall survival (OS); nevertheless, the two groups showed similar results in five-year OS.

conclusionsBased on the available evidence, the addition of surgery to thoracic locally advanced esophageal carcinoma patients with a cCR after neoadjuvant CRT provided no advantage to long-term survival. As an exception, the two-year DFS and OS could be improved. This research conclusion might be more suitable to patients with squamous cell carcinoma.

Indexed as

ChemoradiotherapyEsophagectomyAdenocarcinomaCarcinoma, Squamous CellCombined Modality TherapyEsophageal NeoplasmsFemaleHumansMalePrognosisPublication BiasTreatment OutcomeChemoradiotherapyclinical complete responseesophageal carcinoma

Identifiers

PMID30277016
PMCPMC6275815
OpenAlexW2894947094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.